Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant plus adjuvant Cemiplimab in high-risk resectable stage III cutaneous squamous cell carcinoma
2019-001469-34Phase 2Active
- Sponsor
- Fondazione Melanoma
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Fondazione Melanoma. Primary endpoint: Major pathological response rate. Started Oct 2020; status: active.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2019-001469-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001469-34.